Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.41 |
| ▸ | GLI2 | P10070 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522832 | 1.00 | KDM4E (0.58) | KDM4EOPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL18511509 | 0.91 | KDM4E (0.47) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| SCHEMBL18511507 | 0.91 | KDM4E (0.47) | KDM4ESIGMAR1LTB4RLTB4R2ALDH1A1 | |
| SCHEMBL18522846 | 0.90 | KDM4E (0.46) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| SCHEMBL18511513 | 0.90 | KDM4E (0.46) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| Hydrochloric Acid SCHEMBL18489871 | 0.89 | KDM4E (0.45) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| Hydrochloric Acid SCHEMBL17203024 | 0.89 | KDM4E (0.45) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| SCHEMBL18522836 | 0.88 | KDM4E (0.44) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| SCHEMBL18489859 | 0.88 | KDM4E (0.44) | KDM4ESIGMAR1LMNALTB4RLTB4R2 | |
| SCHEMBL18489870 | 0.82 | PAX8 (0.42) | KDM4ESIGMAR1LTB4RLTB4R2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2022-04-07 | — | — | US | disclosed |
| EP-3388427-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20160068567-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068567-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2014174064-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014174062-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014174060-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, AURKC, DHCR7 | KDM4E 4543/4885OPRM1 2619/4885OPRD1 1090/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | KDM4E 2202/4885OPRM1 3829/4885OPRD1 3835/4885 |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | KDM4E 4446/4885OPRM1 2061/4885OPRD1 814/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | KDM4E 4420/4885OPRM1 2055/4885OPRD1 790/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | KDM4E 2260/4885OPRM1 3122/4885OPRD1 2355/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | KDM4E 2202/4885OPRM1 3829/4885OPRD1 3835/4885 |
| US-20160068567-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | CDK10, AURKC, AURKA | KDM4E 4507/4885OPRM1 4104/4885OPRD1 2501/4885 |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | KDM4E 1659/4885OPRM1 3966/4885OPRD1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.